Base de dados : MEDLINE
Pesquisa : C14.907.079 [Categoria DeCS]
Referências encontradas : 4344 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 435 ir para página                         

  1 / 4344 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28954105
[Au] Autor:Liu F; Hu W; Liu H; Zhang M; Sang H
[Ad] Endereço:Department of Dermatology, Jinling Hospital affiliated to Nanjing University School of Medicine - Jiangsu, China.
[Ti] Título:Episodic angioedema associated with eosinophilia.
[So] Source:An Bras Dermatol;92(4):534-536, 2017 Jul-Aug.
[Is] ISSN:1806-4841
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:We report a 12-year-old girl who presented with recurrent angioedema on the face, trunk, and extremities, and concomitant marked weight gain for 5 years. During the episode, her white blood cell count increased to 47.7×109/L with 89.9% eosinophils, followed by elevated serum level of IL-5, IgE, IgM, and LDH. Histopathology showed perivascular eosinophilic infiltration and diffuse eosinophilic infiltration throughout the dermis. Possible causes of hypereosinophilia and eosinophilic infiltration of vital organs were ruled out. We also tested the FIP1L1/PDGFRa and ETV6/PDGFRb fusion gene to exclude the possibility of myeloid and lymphatic vessel neoplasms. The patient was treated with methylprednisolone and discharged with an oral prednisolone taper, which resulted in complete remission of the edema and normalization of peripheral blood eosinophil count, serum IL-5 level, IgE, IgM, and LDH.
[Mh] Termos MeSH primário: Angioedema/complicações
Eosinofilia/complicações
[Mh] Termos MeSH secundário: Angioedema/patologia
Criança
Eosinofilia/patologia
Feminino
Seres Humanos
Imunoglobulina E/sangue
Imunoglobulina M/sangue
Interleucinas/sangue
Recidiva
Ganho de Peso
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Immunoglobulin M); 0 (Interleukins); 37341-29-0 (Immunoglobulin E)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE


  2 / 4344 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28731410
[Au] Autor:Yazdani R; Abolhassani H; Asgardoon M; Shaghaghi M; Modaresi M; Azizi G; Aghamohammadi A
[Ad] Endereço:Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
[Ti] Título:Infectious and Noninfectious Pulmonary Complications in Patients With Primary Immunodeficiency Disorders.
[So] Source:J Investig Allergol Clin Immunol;27(4):213-224, 2017.
[Is] ISSN:1018-9068
[Cp] País de publicação:Spain
[La] Idioma:eng
[Ab] Resumo:Primary immunodeficiency disorders (PIDs) are caused by 1 or more defects of the immune system. Patients are more likely to experience recurrent and/or severe infections and tend to develop a wide range of complications. Respiratory diseases are the main and initial manifestation in most cases and the most common complication. Pulmonary complications cause significant morbidity and mortality in patients with PIDs. Early diagnosis and appropriate treatment can prevent or at least slow the development of respiratory complications. Since the spectrum of pulmonary complications in PIDs is broad, we divided pulmonary complications into upper respiratory complications (eg, sinusitis, otitis media, and laryngeal angioedema) and lower respiratory complications (eg, pneumonia, bronchitis, bronchiectasis, interstitial lung diseases, organizing pneumonia, pulmonary adenopathies and malignancies, hyperreactive airway diseases, pulmonary dysgenesis, and adverse reactions to treatment). This review covers the main respiratory manifestations in patients with PIDs.
[Mh] Termos MeSH primário: Infecções Bacterianas/etiologia
Síndromes de Imunodeficiência/complicações
Doenças Respiratórias/etiologia
[Mh] Termos MeSH secundário: Angioedema/etiologia
Bronquiectasia/etiologia
Bronquite/etiologia
Pneumonia em Organização Criptogênica/etiologia
Seres Humanos
Edema Laríngeo/etiologia
Doenças Pulmonares Intersticiais/etiologia
Neoplasias Pulmonares/etiologia
Otite Média/etiologia
Pneumonia/etiologia
Sinusite/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE
[do] DOI:10.18176/jiaci.0166


  3 / 4344 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28681416
[Au] Autor:Duke JD; Ryan PB; Suchard MA; Hripcsak G; Jin P; Reich C; Schwalm MS; Khoma Y; Wu Y; Xu H; Shah NH; Banda JM; J Schuemie M
[Ad] Endereço:Observational Health Data Sciences and Informatics (OHDSI) Collaborative.
[Ti] Título:Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network.
[So] Source:Epilepsia;58(8):e101-e106, 2017 Aug.
[Is] ISSN:1528-1167
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Recent adverse event reports have raised the question of increased angioedema risk associated with exposure to levetiracetam. To help address this question, the Observational Health Data Sciences and Informatics research network conducted a retrospective observational new-user cohort study of seizure patients exposed to levetiracetam (n = 276,665) across 10 databases. With phenytoin users (n = 74,682) as a comparator group, propensity score-matching was conducted and hazard ratios computed for angioedema events by per-protocol and intent-to-treat analyses. Angioedema events were rare in both the levetiracetam and phenytoin groups (54 vs. 71 in per-protocol and 248 vs. 435 in intent-to-treat). No significant increase in angioedema risk with levetiracetam was seen in any individual database (hazard ratios ranging from 0.43 to 1.31). Meta-analysis showed a summary hazard ratio of 0.72 (95% confidence interval [CI] 0.39-1.31) and 0.64 (95% CI 0.52-0.79) for the per-protocol and intent-to-treat analyses, respectively. The results suggest that levetiracetam has the same or lower risk for angioedema than phenytoin, which does not currently carry a labeled warning for angioedema. Further studies are warranted to evaluate angioedema risk across all antiepileptic drugs.
[Mh] Termos MeSH primário: Angioedema/induzido quimicamente
Angioedema/epidemiologia
Epilepsia/tratamento farmacológico
Fenitoína/efeitos adversos
Piracetam/análogos & derivados
[Mh] Termos MeSH secundário: Redes Comunitárias/estatística & dados numéricos
Bases de Dados Factuais/estatística & dados numéricos
Feminino
Seres Humanos
Masculino
Piracetam/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
230447L0GL (etiracetam); 6158TKW0C5 (Phenytoin); ZH516LNZ10 (Piracetam)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE
[do] DOI:10.1111/epi.13828


  4 / 4344 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28432171
[Au] Autor:Rigopoulou EI; Ioannou M; Papadamou G; Dalekos GN
[Ad] Endereço:Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, Larissa, Greece.
[Ti] Título:Ascites in a patient with episodic angio-oedema and eosinophilia: thinking outside the box.
[So] Source:BMJ Case Rep;2017, 2017 Apr 21.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Episodic angio-oedema with eosinophilia (EAE) or Gleich's syndrome is a rare condition characterised by recurrent episodes of oedema and eosinophilia, accompanied by urticaria, fever and weight gain. The presence of ascites has not been reported so far. We report a 21-year-old Caucasian woman who presented with marked ocular oedema and ascites. Laboratory evaluation revealed marked eosinophilia. During the last 3 months, three episodes of facial and neck oedema were reported, which resolved spontaneously over a period of 3-5 days. The diagnosis of EAE was established after exclusion of secondary causes (infections, allergic reactions, collagen diseases, neoplasms) and clonal disorders associated with marked eosinophilia. Low-dose steroids resulted in eosinophil decrease and complete resolution of symptoms, including ascites. This case highlights that ascites can be a very rare manifestation of EAE particularly if other more frequent causes of ascites have been excluded and the clinical and laboratory findings are supportive of EAE.
[Mh] Termos MeSH primário: Angioedema/diagnóstico
Ascite/etiologia
Eosinofilia/diagnóstico
[Mh] Termos MeSH secundário: Angioedema/tratamento farmacológico
Eosinofilia/tratamento farmacológico
Feminino
Seres Humanos
Esteroides/uso terapêutico
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Steroids)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170423
[St] Status:MEDLINE


  5 / 4344 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28291095
[Au] Autor:LoVerde D; Files DC; Krishnaswamy G
[Ad] Endereço:1Division of Pulmonary, Critical Care, Allergy and Immunology, Department of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC.2Division of Allergy and Clinical Immunology, Department of Medicine, W.G. (Bill) Hefner VA Medical Center, Salisbury, NC.
[Ti] Título:Angioedema.
[So] Source:Crit Care Med;45(4):725-735, 2017 Apr.
[Is] ISSN:1530-0293
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Angioedema is a potentially life-threatening occurrence that is encountered by critical care providers. The mechanistic understanding of angioedema syndromes has improved in recent years, and novel medications are available that improve outcomes from these syndromes. This clinically focused review will describe the underlying genetics, pathophysiology, classification and treatment of angioedema syndromes, with an emphasis on the novel pharmacologic agents that have recently become available for acute treatment. DATA SOURCES: A MEDLINE search was conducted with the MeSH terms angioedema, acquired angioedema, hereditary angioedema type III, and angiotensin converting enzyme inhibitor-induced angioedema. STUDY SELECTION: Selected publications describing angioedema, clinical trials, diagnosis, management, and genetics were retrieved (reviews, guidelines, clinical trials, case series), and their bibliographies were also reviewed to identify relevant publications. DATA EXTRACTION: Data from the relevant publications were reviewed, summarized and the information synthesized. DATA SYNTHESIS: The data obtained were used to describe the current state of diagnosis and management of various angioedema syndromes. CONCLUSIONS: Angioedema is a life-threatening syndrome with multiple subtypes, each with a distinct pathophysiology. We present an evidence-based approach to the diagnosis and suggested management of various subtypes of angioedema. Securing the airway remains the most important intervention, followed by administration of both established and more novel pharmacologic interventions based on disease pathology.
[Mh] Termos MeSH primário: Manuseio das Vias Aéreas
Angioedema/classificação
Angioedema/terapia
[Mh] Termos MeSH secundário: Angioedema/diagnóstico
Angioedema/genética
Bradicinina/análogos & derivados
Bradicinina/uso terapêutico
Antagonistas de Receptor B2 da Bradicinina/uso terapêutico
Proteínas Inativadoras do Complemento 1/uso terapêutico
Proteína Inibidora do Complemento C1/uso terapêutico
Cuidados Críticos
Seres Humanos
Calicreínas/antagonistas & inibidores
Peptídeos/uso terapêutico
Proteínas Recombinantes/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Bradykinin B2 Receptor Antagonists); 0 (Complement C1 Inactivator Proteins); 0 (Complement C1 Inhibitor Protein); 0 (Peptides); 0 (Recombinant Proteins); 0 (SERPING1 protein, human); 0 (conestat alpha); 5Q6TZN2HNM (ecallantide); 7PG89G35Q7 (icatibant); EC 3.4.21.- (Kallikreins); S8TIM42R2W (Bradykinin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170315
[St] Status:MEDLINE
[do] DOI:10.1097/CCM.0000000000002281


  6 / 4344 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28282682
[Au] Autor:Schadow C; Wex C; Wybranski C; Kalinski T; Schulz C; Meyer F
[Ad] Endereço:Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Universitätsklinikum Magdeburg A.ö.R.
[Ti] Título:[Angioneurotic Edema as a Differential Diagnosis of Recurrent Abdominal Pain].
[Ti] Título:Angioneurotisches Ödem als Differenzialdiagnose rezidivierender Bauchschmerzen..
[So] Source:Dtsch Med Wochenschr;142(5):341-345, 2017 Mar.
[Is] ISSN:1439-4413
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:A 46-year-old woman was admitted because of recurrent postprandial vomiting including weight loss of 30 kg within the last 5 - 6 months. The physical investigation was indicative of preileus. CT scan revealed an unclear thickening of the jejunum. Explorative laparotomy was performed because of the considerable degree of suffering and a tendency of worsening. Intraoperatively, the preoperatively observed thickening was confirmed at 3 subsequent segments of the jejunum (3 cm long each) prompting to segmental resection of the jejunum. The postoperative course was uneventful. Histopathology revealed submucous, partially transmural, segmental edema compatible with an angioneurotic edema. Amyloidosis, sprue and malignancy could be excluded. A C1 esterase inhibitor test war normal. A further search for possible causes revealed ACE inhibitor medication for hypertension. The differential diagnostic assessment of isolated small intestine diseases must take into account rare systemic disease. The knowledge of the history of medicine can be useful to detect the - not mandatory - connection to angioedema.
[Mh] Termos MeSH primário: Dor Abdominal/induzido quimicamente
Dor Abdominal/diagnóstico
Angioedema/induzido quimicamente
Angioedema/diagnóstico
Inibidores da Enzima Conversora de Angiotensina/efeitos adversos
Doenças do Jejuno/induzido quimicamente
[Mh] Termos MeSH secundário: Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Diagnóstico Diferencial
Feminino
Seres Humanos
Hipertensão/complicações
Hipertensão/tratamento farmacológico
Doenças do Jejuno/diagnóstico
Meia-Idade
Recidiva
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170403
[Lr] Data última revisão:
170403
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170311
[St] Status:MEDLINE
[do] DOI:10.1055/s-0042-100095


  7 / 4344 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28234051
[Au] Autor:Arik Yilmaz E; Karaatmaca B; Cetinkaya PG; Soyer O; Sekerel BE; Sahiner UM
[Ti] Título:The persistence of chronic spontaneous urticaria in childhood is associated with the urticaria activity score.
[So] Source:Allergy Asthma Proc;38(2):136-142, 2017 03 01.
[Is] ISSN:1539-6304
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: There is little information regarding the etiology and natural course of chronic spontaneous urticaria (CSU) in childhood. OBJECTIVE: To investigate the etiology, prognosis, and the factors associated with the prognosis of CSU in children. METHOD: Data from children with CSU who had been diagnosed between 1992 and 2015 were analyzed. A telephone interview was done to assess the current status of these patients. Remission was defined as the disappearance of urticaria for >6 months. RESULTS: A total of 222 children with CSU were evaluated. The median age of symptom onset was 8.8 years (interquartile range [IQR], 4.6-12.3 years), median duration of urticaria was 23 months (IQR, 7-48 months), and the median sum of the daily urticaria activity score of 7 consecutive days (UAS7) was 28 (IQR, 21-42). Accompanying angioedema was reported by 107 patients (48.2%), whereas 27.1% of the study population had autoantibody positivity. Autologous serum skin testing results were positive in 43 (34.1%); skin-prick testing results revealed atopy in 55 children (27.9%). Parasites (4.8%), pollen sensitization (1.5%), food allergy (0.9%), urinary tract infection (0.9%), and Hashimoto thyroiditis (0.5%) were determined as etiologic factors of CSU. The patients were followed up for a median time of 15 months (IQR, 5-36.5 months). Remission was observed in 10.6, 29.3, and 44.5% of the patients in 1, 3, and 5 years, respectively. In multivariate regression analysis, a UAS7 of >28 at admission was found to be a risk factor for persistence of urticaria (odds ratio 6.22 [95% confidence interval, 1.54-25.15; p = 0.010). CONCLUSION: The etiology of CSU in children was mostly idiopathic despite detailed investigation. In childhood, the natural course of CSU was favorable, and nearly half of the patients recovered after 5 years of disease duration. A high UAS7 at admission seemed to be a significant risk factor for the persistence of symptoms.
[Mh] Termos MeSH primário: Urticária/fisiopatologia
[Mh] Termos MeSH secundário: Adolescente
Angioedema/etiologia
Angioedema/imunologia
Angioedema/fisiopatologia
Animais
Infecções por Blastocystis/complicações
Infecções por Blastocystis/imunologia
Criança
Pré-Escolar
Doença Crônica
Dientamebíase/complicações
Dientamebíase/imunologia
Progressão da Doença
Feminino
Seguimentos
Hipersensibilidade Alimentar/complicações
Hipersensibilidade Alimentar/imunologia
Giardíase/complicações
Giardíase/imunologia
Doença de Hashimoto/complicações
Seres Humanos
Masculino
Análise Multivariada
Razão de Chances
Prognóstico
Modelos de Riscos Proporcionais
Remissão Espontânea
Rinite Alérgica Sazonal/complicações
Rinite Alérgica Sazonal/imunologia
Fatores de Risco
Índice de Gravidade de Doença
Testes Cutâneos
Infecções Urinárias/complicações
Urticária/etiologia
Urticária/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170225
[St] Status:MEDLINE
[do] DOI:10.2500/aap.2017.38.4029


  8 / 4344 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28226314
[Au] Autor:Blockhuys M; Faber MA; Sabato V; Hubens G; Ebo DG
[Ad] Endereço:Department of Abdominal Surgery, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium.
[Ti] Título:Bariatric Surgery: A Novel Risk Factor for Food Allergy?
[So] Source:Int Arch Allergy Immunol;172(1):64-66, 2017.
[Is] ISSN:1423-0097
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:In this case report, we describe a birch pollen-allergic patient in whom a Fobi pouch gastric bypass was associated with the transition from a mild, localized, birch pollen-related oral allergy syndrome to more severe, generalized allergic reactions to peach.
[Mh] Termos MeSH primário: Betula/imunologia
Hipersensibilidade Alimentar/etiologia
Frutas/imunologia
Derivação Gástrica/efeitos adversos
Pólen/imunologia
Prunus persica/imunologia
[Mh] Termos MeSH secundário: Angioedema/patologia
Dispneia/patologia
Feminino
Seres Humanos
Imunoglobulina E/sangue
Meia-Idade
Rinite Alérgica Sazonal
Urticária/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
37341-29-0 (Immunoglobulin E)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170327
[Lr] Data última revisão:
170327
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170223
[St] Status:MEDLINE
[do] DOI:10.1159/000455123


  9 / 4344 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28225685
[Au] Autor:Longhurst HJ
[Ad] Endereço:From the Barts Health NHS Trust, London.
[Ti] Título:Kallikrein Inhibition for Hereditary Angioedema.
[So] Source:N Engl J Med;376(8):788-789, 2017 02 23.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Angioedema
Angioedemas Hereditários
[Mh] Termos MeSH secundário: Seres Humanos
Calicreínas
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
EC 3.4.21.- (Kallikreins)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170224
[Lr] Data última revisão:
170224
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170223
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMe1611929


  10 / 4344 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28219067
[Au] Autor:Asero R; Marzano AV; Ferrucci S; Cugno M
[Ad] Endereço:Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.
[Ti] Título:D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria.
[So] Source:Int Arch Allergy Immunol;172(1):40-44, 2017.
[Is] ISSN:1423-0097
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Omalizumab is very effective in the majority of patients with severe chronic spontaneous urticaria (CSU), but its mechanism of action is still unclear. In CSU the coagulation cascade is activated with an intensity that parallels the disease severity, and elevated plasma D-dimer levels are associated with a poor response to both antihistamines and cyclosporin. We measured D-dimer plasma levels before and after the first administration of omalizumab in 32 patients with severe CSU. A number of clinical and laboratory parameters were recorded, including the urticaria activity score, presence of angioedema, disease duration, C-reactive protein, anti-nuclear, and anti-thyroid antibodies. Baseline D-dimer levels were elevated in 19 (59%) cases. Omalizumab induced a complete response in 25 patients (78%), in most cases already after the first administration. At baseline, 14/25 responders had increased D-dimer plasma levels versus 5/7 non-responders. All responders showed a dramatic decrease of D-dimer plasma levels after the first administration of the drug (from 1,024 ± 248 [mean ± SE] to 251 ± 30 ng/mL; p = 0.003). In contrast, non-responders did not show any reduction in D-dimer levels after omalizumab administration (from 787 ± 206 to 1,230 ± 429 ng/mL; p = ns). In conclusion, plasma levels of D-dimer are frequently elevated in patients with severe CSU before omalizumab administration and decrease according to the clinical response of the disease to the drug, suggesting a possible effect of omalizumab on coagulation activation and fibrin degradation in a subset of CSU patients.
[Mh] Termos MeSH primário: Antialérgicos/uso terapêutico
Produtos de Degradação da Fibrina e do Fibrinogênio/uso terapêutico
Omalizumab/uso terapêutico
Urticária/tratamento farmacológico
Urticária/patologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Angioedema/patologia
Anticorpos Antinucleares/sangue
Coagulação Sanguínea/efeitos dos fármacos
Proteína C-Reativa/metabolismo
Feminino
Produtos de Degradação da Fibrina e do Fibrinogênio/análise
Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo
Seres Humanos
Masculino
Meia-Idade
Urticária/sangue
Urticária/imunologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Antibodies, Antinuclear); 0 (Fibrin Fibrinogen Degradation Products); 0 (fibrin fragment D); 2P471X1Z11 (Omalizumab); 9007-41-4 (C-Reactive Protein)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170327
[Lr] Data última revisão:
170327
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170221
[St] Status:MEDLINE
[do] DOI:10.1159/000453453



página 1 de 435 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde